Medmain Speaks

We a happy to announce that we have raised approximately 1.1 billion yen through a private placement of new shares by multiple hospital groups, venture capitalists, businesses, and private investors. With the recent demand for the rapid development of a diagnostic system after the COVID-19 pandemic, Medmain Inc. will continue to support medical professionals across the country, especially those who are on the front lines of pathology diagnosis. About Fundraising

Deep Learning has been used in various medical fields recently especially in radiology and pathology where medical image recognition has been used frequently. We have announced in January 2020 the establishment of an AI model to detect epithelial tumors in the stomach and colon, and this has been published by Scientific Reports. (Scientific Reports 2020, volume 10, Article (number: 1504) We are so pleased to announce that on June 9th, 2020, our paper co-authored by the doctors from the National Hospital Organization Kyushu Medical Center and members of Medmain Inc.

Our CEO Osamu Iizuka was selected for the Forbes 30 Under 30 - Asia’s Healthcare & Science category as announced by Forbes on April 2(JST) . 【About Forbes 30 Under 30 Asia】Forbes selects young entrepreneurs, leaders and changemakers who are under the age of 30 in their respective fields in 23 countries and regions across

Medmain Inc. a Japanese health tech startup has launched its service “PidPort, a platform service for pathological image diagnosis, which includes Deep Learning driven pathological analysis.

Medmain Inc. and Kyushu Daigaku Kigyobu (a startup activity club of Kyushu University) were together awarded the Minister of Education, Culture, Sports, Science and Technology’s award of the 2nd ” Japan Open Innovation Prize “.